Jane Street Portfolio holdings
Jane Street Group, founded in 2000 by Tim Reynolds, Rob Granieri, Marc Gerstein, and Michael Jenkins, is a New York City-based quantitative trading firm renowned for its technological prowess and collaborative problem-solving culture. Specializing in liquidity provision and market-making, it trades a vast array of financial products—including equities, bonds, options, and ETFs—across over 200 venues in 45 countries, handling trillions in securities annually. The firm, which employs over 2,600 people across offices in New York, London, Hong Kong, Amsterdam, Chicago, and Singapore, leverages advanced algorithms and a nearly 70-million-line OCaml codebase to dominate markets, notably ETFs, where it plays a critical role as an authorized participant. With net trading revenues exceeding $10 billion annually in recent years, including a record $10.6 billion in 2023, Jane Street has emerged as a secretive yet powerful force in global finance, outpacing traditional Wall Street giants like Goldman Sachs in trading profitability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.52B |
| 2 |
NVIDIA
NVDA
|
+$732M |
| 3 |
ProShares UltraPro QQQ
TQQQ
|
+$555M |
| 4 |
Dell
DELL
|
+$542M |
| 5 |
Schwab Short-Term US Treasury ETF
SCHO
|
+$421M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.18B |
| 2 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$1.29B |
| 3 |
Visa
V
|
+$1.12B |
| 4 |
iShares Core MSCI EAFE ETF
IEFA
|
+$918M |
| 5 |
Broadcom
AVGO
|
+$892M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 2.93% |
| 2 | Consumer Discretionary | 1.52% |
| 3 | Healthcare | 0.84% |
| 4 | Financials | 0.83% |
| 5 | Communication Services | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
9126
Protalix BioTherapeutics
PLX
$198M
| $46.9K | ﹤0.01% |
45,952
-244,307
| -84% | -$257K |
|
9127
Citius Pharmaceuticals
CTXR
$18.7M
| $46.8K | ﹤0.01% |
3,738
-11,603
| -76% | -$195K |
|
|
AISPW
9128
Airship AI Holdings Warrants
AISPW
$15.2M
| $46.5K | ﹤0.01% |
221,583
| – | – |
|
|
RGLS
9129
DELISTED
Regulus Therapeutics
RGLS
| $46.4K | ﹤0.01% |
+29,580
| New | +$48.9K |
|
|
KZR
9130
DELISTED
Kezar Life Sciences
KZR
| $46K | ﹤0.01% |
5,954
-48,952
| -89% | -$295K |
|
9131
Nerdy
NRDY
$96.7M
| $46K | ﹤0.01% |
46,814
-107,223
| -70% | -$137K |
|
9132
Verastem
VSTM
$610M
| $45.4K | ﹤0.01% |
15,192
-16,806
| -53% | -$45.6K |
|
9133
Ovid Therapeutics
OVID
$491M
| $45.3K | ﹤0.01% |
38,399
-60,191
| -61% | -$62.9K |
|
9134
TMC The Metals Company
TMC
$1.98B
| $44.8K | ﹤0.01% |
42,288
-1,144
| -3% | -$1.28K |
|
|
AFMD
9135
DELISTED
Affimed
AFMD
| $44.5K | ﹤0.01% |
+13,240
| New | +$58.4K |
|
9136
CALL
SELLAS Life Sciences
SLS
$2.36B
| $43.8K | ﹤0.01% |
35,000
+25,000
| +250% | +$30.6K |
|
|
HIVE
9137
PUT
HIVE Digital Technologies
HIVE
$777M
| $43.4K | ﹤0.01% |
+13,600
| New | +$44.3K |
|
|
ASM
9138
Avino Silver & Gold Mines
ASM
$1.2B
| $43.1K | ﹤0.01% |
39,184
+28,771
| +276% | +$29K |
|
9139
5E Advanced Materials
FEAM
$62.3M
| $42.6K | ﹤0.01% |
3,623
-3,092
| -46% | -$58.5K |
|
|
ATYR
9140
aTyr Pharma
ATYR
$50.1M
| $41.8K | ﹤0.01% |
23,754
-4,702
| -17% | -$8.55K |
|
9141
PUT
Kosmos Energy
KOS
$1.48B
| $41.5K | ﹤0.01% |
10,300
-5,300
| -34% | -$25.8K |
|
|
SJT
9142
PUT
San Juan Basin Royalty Trust
SJT
$118M
| $41.1K | ﹤0.01% |
+11,100
| New | +$41.5K |
|
9143
TH International
THCH
$56.7M
| $40.6K | ﹤0.01% |
+10,024
| New | +$33.6K |
|
9144
CALL
BRC Inc
BRCC
$250M
| $39.7K | ﹤0.01% |
+11,600
| New | +$53.2K |
|
9145
Torrid Holdings
CURV
$260M
| $39.6K | ﹤0.01% |
10,079
-3,892
| -28% | -$26.2K |
|
|
CMBM
9146
DELISTED
Cambium Networks
CMBM
| $39.3K | ﹤0.01% |
21,482
-7,821
| -27% | -$14.8K |
|
9147
D-Wave Quantum Inc. Common Stock
QBTS
$7.73B
| $39.2K | ﹤0.01% |
39,922
-63,110
| -61% | -$63.1K |
|
9148
CALL
Editas Medicine
EDIT
$442M
| $37.9K | ﹤0.01% |
11,100
-1,300
| -10% | -$5.66K |
|
|
CIK
9149
Credit Suisse Asset Management Income Fund
CIK
$134M
| $37.3K | ﹤0.01% |
+12,087
| New | +$36.9K |
|
|
JBIO
9150
Jade Biosciences
JBIO
$1.34B
| $37.2K | ﹤0.01% |
509
-2,641
| -84% | -$170K |
|
Similar funds
Jane Street's Q3 2024 Portfolio in Review
As of Q3 2024, Jane Street held 10,828 positions worth $453B, up 3.6% from $438B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Jane Street withdrew a net $18.5B in Q3 2024, closing 1,349 positions and reducing 4,327 holdings. Its most notable exit was iShares Core MSCI International Developed Markets ETF, an estimated $290M position sold in full.
By sector, the portfolio is most concentrated in Technology at 2.9% of assets, down from 4.6% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jane Street opened a new position in Schwab Short-Term US Treasury ETF worth $424M.
- Jane Street's largest Q3 2024 buy was Schwab Short-Term US Treasury ETF: 17,304,274 shares worth $424M.
- Jane Street added most to State Street SPDR S&P 500 ETF Trust in Q3 2024, an estimated $2.52B increase.
- Jane Street's biggest Q3 2024 reduction was Apple, cutting an estimated $4.18B.
- Jane Street fully exited iShares Core MSCI International Developed Markets ETF in Q3 2024, selling an estimated $290M.
- Jane Street's ten largest holdings make up 44% of its $453B portfolio in Q3 2024.
- Jane Street opened 1,593 new positions and closed 1,349 in Q3 2024.
- Jane Street's portfolio value rose 3.6% quarter-over-quarter to $453B.
Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.